A Focus on Quality-of-Life

CME

Risk Adapted Treatment of Myelofibrosis: A Focus on Quality-of-Life

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: September 22, 2022

Expiration: September 22, 2023

John Mascarenhas
John Mascarenhas, MD
Ruben Mesa
Ruben Mesa, MD, FACP

Pretest

Progress
1 2
Course Completed
1.

How confident are you in your ability to treat your patients with myelofibrosis?

2.

Your patient is a 68-year-old male who has had PV for 9 years but is experiencing progressive fatigue, weight loss, and night sweats; he is transfusion independent. He is diagnosed with post-PV myelofibrosis based on the following laboratory results: Platelets 117 x 10(9)/L, Hb 9.7 g/dL, WBC: 27 x 10(9)/L, 2% myelocytes on peripheral smear.

Based on this information, how would you categorize this patient’s risk? 

3.

The 68-year-old patient from question 3 does not have a sibling match donor for stem cell transplant and is interested in beginning pharmacologic therapy as soon as possible to slow the progression of disease.  (Platelets 117 x 10(9)/L, Hb 9.7 g/dL, WBC: 27 x 10(9)/L) 

Which of the following treatments would you consider for this patient? 

4.

Which of the following strategies has been shown to be most effective in mitigating the risk of encephalopathy in patients receiving fedratinib? 

5.

What were the three most common symptoms reported by patients with myelofibrosis in the MPN Landmark study?